News
ABEO
3.950
-1.74%
-0.070
SENS, YELL and ABEO are among pre market gainers
InVivo Therapeutics Holdings (NVIV) +106%. GreenLigh...
Seekingalpha · 5d ago
Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement
Abeona Therapeutics (NASDAQ:ABEO) received Nasdaq notification ...
Seekingalpha · 07/20 11:47
Abeona Therapeutics Regains Compliance With Nasdaq Listing Requirements
Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained compliance with the minimum bid price
Benzinga · 07/20 11:34
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained compliance with the m...
GlobeNewswire · 07/20 11:30
Abeona Therapeutics Says It Regains Compliance With Nasdaq's Minimum Bid Price Rule
MT Newswires · 07/20 09:15
Abeona crashes 21% as reverse stock split takes effect
Nano-cap clinical stage biotech Abeona Therapeutics (NASDAQ:ABEO</a...
Seekingalpha · 07/05 13:25
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 07/05 11:26
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Zacks · 06/24 14:08
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy
An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.
Zacks · 06/13 17:27
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.
Zacks · 06/10 19:30
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Investor Place · 06/10 11:27
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Zacks · 06/08 17:21
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.
Zacks · 06/06 18:04
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on...
GlobeNewswire · 06/06 11:30
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
Zacks · 06/01 18:25
Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
Zacks · 05/31 18:27
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
Zacks · 05/25 18:29
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.
Zacks · 05/19 19:02
Abeona Therapeutics gets additional 180-day to regain Nasdaq compliance
Abeona Therapeutics (NASDAQ:ABEO) has been granted additional 180-day by Nasdaq to regain compliance with the $1.00 minimum bid price requirement for continued listing. Common stock continues to trade on the
Seekingalpha · 05/19 12:01
Abeona Therapeutics Granted Second 180-day Period By Nasdaq To Regain Compliance With Minimum Bid Price Rule
Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq’s Listing Qualification
Benzinga · 05/19 11:36
More
Webull provides a variety of real-time ABEO stock news. You can receive the latest news about Abeona Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB) and ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA). The Company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM Capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs. It is applying AIM Capsid Technology to develop in-vivo gene therapies.